At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Durvalumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist Poly-ICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Tremelimumab, and 1 other intervention for Head and Neck Squamous Cell Carcinoma and 10 related conditions. Completed, enrolled 58 participants across 7 sites.
Detailed Summary
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
CountriesUnited States
CollaboratorsMedImmune LLC, Cancer Research Institute, New York City
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartDec 2016
Primary CompletionFeb 2022
TodayJul 2026
First PostedDec 31, 2015
Enrollment StartDec 28, 2016
Primary CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 10.5 years ago
Interventions
Durvalumabdrug
Tremelimumabdrug
Poly-ICLCdrug